The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance

Regulatory Peptides

Volumn 65, Issue 1, 1996, Pages 23-28

  Wiesenfeld Hallin, Zsuzsanna ^a   Xu, Xiao Jun ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; LORGLUMIDE; LY 262691; MORPHINE; PROGLUMIDE; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DRUG TOLERANCE; HUMAN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATOSENSORY SYSTEM;

EID: 0030603863     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-0115(96)00068-7     Document Type: Review

References (59)

1. [1] Wiesenfeld-Hallin, Z. and Xu, X-J., Role of cholecystokinin type B receptor in nociception studied with peptide agonists and antagonists. In: P.M. Conn (Ed.), Methods in Neurosciences, Vol. 11, Academic Press, San Diego, CA, 1993, pp. 148-169.
2. [2] Hökfelt, T., Zhang, X. and Wiesenfeld-Hallin, Z., Messenger plasticity in primary sensory neurons following axotomy and its functional implications, Trends Neurosci., 17 (1994) 22-30.
3. [3] Williams, R.G., Dimaline, R., Varro, A., Isetta, A.M., Trizio, D. and Dockray, G.J., Cholecystokinin octapeptide in rat central nervous system: immunocytochemical studies using a monoclonal antibody that does not react with CGRP, Neurochem. Int., 11 (1987) 433-442.
4. [4] Schiffmann, S.N. and Vanderhaeghen, J.J., Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J. Comp. Neurol., 304 (1991) 219-233.
5. [5] Baber, N.S., Dourish, C.T. and Hill, D.R., The role of CCK, caerulein, and CCK antagonists in nociception, Pain, 39 (1989) 307-328.
6. [6] Dalsgaard, C.J., Vincent, S.R., Hökfelt, T., Lundberg, J.M., Dahlström, A., Schultzberg, M., Dockray, G.J. and Cuello, A.C., Coexistence of cholecystokinin and substance P-like peptides in the neurons of the dorsal root ganglia of the rat, Neurosci. Lett., 33 (1982) 159-163.
7. [7] Ju, G., Hökfelt, T., Fischer, J.A., Frey, P., Rehfeld, J.F. and Dockray, G.J., Does cholecystokinin-like immunoreactivity in rat primary sensory neuorns represent calcitonin gene-related peptide? Neurosci. Lett., 68 (1986) 305-310.
8. [8] Seroogy, K.B., Mohapatra, N.K., Lund, P.K., Réthelyi, M., McGehee, D.S. and Perl, E.R., Species-sepcific expression of cholecystokinin messenger RNA in rodent dorsal root ganglia, Mol. Brain Res., 7 (1990) 171-176.
9. [9] Verge, V.M.K., Wiesenfeld-Hallin, Z. and Hökfelt, T., Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies in rat and monkey, Eur. J. Neurosci., 5 (1993) 240-250.
10. [10] Zhang, X., Ju, G., Elde, R. and Hökfelt, T. (1993) Effect of peripheral nerve cut on neuropeptides in dorsal root ganglia and the spinal cord of monkey with special reference to galanin, J. Neurocytol., 22 (1993) 342-381.
11. [11] Zhang, X., Nicholas, A.P. and Hökfelt, T., Ultrastructural studies on peptides in the dorsal horn of the rat spinal cord. 2. Coexistence of galanin with other peptides in local neurons, Neuroscience, 64 (1995) 875-891.
12. [12] Skirboll, L., Hökfelt, T., Dockray, G., Gehfeld, J., Brownstein, M. and Cuello, A.C., Evidence of periaqueductal cholecystokinin-substance P neurons projecting to the spinal cord, J. Neurosci., 3 (1983) 1151-1157.
13. [13] Zouaoui, D., Benoliel, J.J., Cesselin, F. and Conrath, M., Cholecystokinin-like immunoreactivity in the rat spinal cord: effects of thoracic transection, Brain. Res. Bull., 26 (1991) 543-547.
14. [14] Jacquin, M.F., Beinfeld, M.C., Chiaia, N.L. and Zahm, D.S., Cholecystokinin concentrations and peptide immunoreactivity in the intact and deafferented medullary dorsal horn of the rat, J. Comp. Neurol., 326 (1992) 22-43.
15. [15] Innis, R.B. and Snyder, S.H., Distinct cholecystokinin receptors in brain and pancreas, Proc. Natl. Acad. Sci. USA, 77 (1980) 6917-6921.
16. [16] Moran, T., Robinson, P., Goldrich, M.S. and McHugh, P., Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res., 362 (1986) 175-179.
17. [17] Hill, D.R. and Woodruff, G.N., Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260, Brain Res., 526 (1990) 276-283.
18. 3H-MK-329, J. Neurosci., 10 (1990) 1070-1081.
19. [19] Ghilardi, J.R., Allen, C.J., Vigna, S.R., McVey, D.C. and Mantyh, P.W., Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit and monkey: possible site of opiate-CCK analgesic interactions. J. Neurosci., 12 (1992) 4854-4866.
20. [20] Zhang, X,. Dagerlind, Å., Elde, R.P., Castel, M.N., Broberger, C., Wiesenfeld-Hallin, Z. and Hökfelt, T., Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy, Neuroscience, 57 (1993) 227-233.
21. [21] Showell, G.A., Bourrain, S., Neduvelil, J.G., Fletcher, S.R., Baker, R., Watt, A.P., Fletcher, A.E., Freedman, S.B., Kemp, J.A., Marshall, G.R., Patel, S., Smith, A.J. and Matassa, V.G., High affinity and potent, water-soluable 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group, J. Med. Chem., 37 (1994) 719-721.
22. [22] Schiantarelli, P., Theraputic potentials of cholecystokinin receptor antagonists in CNS disorders, Pharmacol. Res., 28 (1993) 1-9.
23. [23] Faris, P.L., Komisaruk, B.R., Watkins, L.R. and Mayer, D.J., Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia, Science, 219 (1983) 310-312.
24. [24] Han, J.S., Ding, X.Z. and Fan, X.G., Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous antiopioid substrates, Neuropeptides, 5 (1985) 399-402.
25. [25] Wiesenfeld-Hallin, Z. and Duranti, R., Intrathecal cholecystokinin interacts with morphine but not substance P in modulating the nociceptive flexion reflex in the rat, Peptides, 8 (1987) 153-158.
26. [26] O'Neill, M.F., Dourish, C.T. and Iversen, S.D., Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329, Neuropharmacology, 28 (1989) 243-247.
27. [27] Kellstein, D.E. and Mayer, D.J., Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance, Pain, 47 (1991) 221-229.
28. [28] Magnuson, D.S., Sullivan, A.F., Simonnet, G., Roques, B.P. and Dickenson, A.H., Differential interactions of cholecystokinin and FLFQPQRF-NH2 with mu and delta opioid antinociception in the rat spinal cord, Neuropeptides, 16 (1990) 213-218.
29. [29] Wang, X.J., Wang, X.H. and Han, J.S., Cholecystokinin octapeptide antagonized opioid analgesia mediated by μ,-and κ-but not δ-receptors in the spinal cord of the rat, Brain Res., 523 (1990) 5-10.
30. [30] Watkins, L.R., Kinscheck, I.B. and Mayer, D.J., Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide, Science, 224 (1984) 395-396.
31. [31] Han, J.S., Ding, X.Z. and Fan, S.G., Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance, Pain, 27 (1986) 101-115.
32. [32] Noble, F., Blommaert, A., Fournie-Zaluski, M.C. and Roques, B.P., A selective CCK-B receptor antagonist potentiates mu-, but not delta-opioid receptor-mediated antinociception in the formalin test, Eur. J. Pharmacol., 273 (1995) 145-151.
33. [33] Xu, X-J. and Wiesenfeld-Hallin, Z., Neither cholecystokinin nor galanin modulate intrathecal clonidine-induced depression of the nociceptive flexor reflex in the rat, Brain Res., 621 (1993) 267-271.
34. [34] Watkins, L.R., Kinscheck, I.B., Kaufman, E.F., Miller, J., Frenk, H. and Mayer, D.J., Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates, Brain Res., 327 (1985) 181-190.
35. [35] Dourish, C.T., O'Neill, M.F., Coughlan, J., Kitchener, S.J., Hawley, D. and Iversen, S.D., The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat, Eur. J. Pharmacol., 176 (1990) 35-44.
36. [36] Wiesenfeld-Hallin, Z., Xu, X-J., Hughes, J., Horwell, D.C. and Hökfelt, T., PD134308, a selective antagonist of cholecystokinin type-B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes, Proc. Natl. Acad. Sci. USA, 87 (1990) 7105-7109.
37. [37] Zhou, Y., Sun. Y.H., Zhang, Z.W. and Han, J.S., Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCKB receptor antagonist L365,260 in rat spinal cord, Eur. J. Pharmacol., 234 (1993) 147-154.
38. 5]enkephalin antiserum-sensitive enhancement of morphine antinociception, NeuroReport, 5 (1994) 1-5.
39. [39] Chapman, V., Honore, P., Buritova, J. and Besson, J-M., Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-fos expression in the spinal cord of the rat, Neuroscience, 67 (1995) 731-739.
40. [40] Valverde, O., Maldonado, R., Fournie-Zaluski, M.C. and Roques, B.P., Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins, J. Pharmacol. Exp. Ther., 270 (1994) 77-88.
41. [41] Wang, X.J. and Han, J.S., Modification by cholecystokinin octapeptide of the binding of μ, δ-and κ-opioid receptors, J. Neurochem., 55 (1989) 1379-1382.
42. [42] Wang, J.F., Ren, M.F. and Han, J.S., Mobilization of calcium from intracellular stores is one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide, Peptides, 13 (1992) 947-951.
43. [43] Wiertelak, E.P., Maier, S.F. and Watkins, L.R., Cholecystokinin antianalgesia: safety cues abolish morphine analgesia, Science, 256 (1992) 830-833.
44. [44] Tang, J., Chou, J., Iadarola, M., Yang, H.Y. and Costa, E., Proglumide prevents and curtails acute tolerance to morphine in rats, Neuropharmacology, 23 (1984) 715-718.
45. [45] Benoliel, J.J., Bourgoin, S., Mauborgne, A., Legrand, J.C., Hamon, M. and Cesselin, F., Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation. Neurosci. Lett., 124 (1991) 204-207.
46. [46] Ding, X.Z. and Bayer, B.M., Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine, Brain Res., 625 (1993) 139-144.
47. [47] Xu, X-J., Wiesenfeld-Hallin, Z., Hughes, J., Horwell, D.C. and Hökfelt, T., CI988, a selective antagonist of cholecystokinin type-B receptor, prevents morphine tolerance in the rat, Br. J. Pharmacol., 105 (1992) 591-596.
48. [48] Hoffmann, O. and Wiesenfeld-Hallin, Z., The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats, NeuroReport, 5 (1995) 2565-2568.
49. [49] Zhou, Y., Sun, Y.H., Zhang, Z.W. and Han, J.S., Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine, NeuroReport, 3 (1992) 1121-1123.
50. [50] Xu, X-J. and Wiesenfeld-Hallin, Z. (1991) The threshold for the depressive effect of intrathecal morphine on the spinal nociceptive flexor reflex is increased during autotomy after sciatic nerve section in rats, Pain, 46 (1991) 223-229.
51. [51] Mao, J., Price, D.D. and Mayer, D.J., Experimental mononeuropathy reduces the antinociceptive effect of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain, Pain, 61 (1995) 353-364.
52. [52] Xu, X-J., Puke, M.J.C., Verge, V.M.K., Wiesenfeld-Hallin, Z., Hughes, J. and Hökfelt, T., Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain, Neurosci. Lett. 152 (1993) 129-132.
53. [53] Xu, X-J., Hökfelt, T., Hughes, J. and Wiesenfeld-Hallin, Z., The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats, NeuroReport, 5 (1994) 718-720.
54. [54] Stanfa, L.C. and Dickenson, A.H., Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation, Br. J. Pharmacol., 108 (1993) 967-973.
55. [55] Xu, X-J., Hao, J-X., Seiger, Å., Hughes, J., Hökfelt, T. and Wiesenfeld-Hallin, Z., Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems, Pain, 56 (1994) 271-278.
56. [56] Kellstein, D.E., Price, D.D. and Mayer, D.J., Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons, Brain Res., 540 (1991) 302-306.
57. [57] Rattray, M., Jordan, C.C. and DeBelleroche, J., The novel CCK antagonist L364,718 abolishes caerulein but potentiates morphine-induced antinociception, Eur. J. Pharmacol., 152 (1988) 163-166.
58. [58] Derrien, M., Noble, F., Maldonado, R. and Roques, B.P., (1993) Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice, Neurosci. Lett., 160 (1993) 193-196.
59. [59] Dourish, C.T., O'Neill, M.F., Schaffer, L.W., Siegel, P.K.S. and Iversen, S.D., The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey, J. Pharmacol. Exp. Ther., 255 (1990) 1158-1165.